ADMA Biologics, Inc.ADMANASDAQ
Loading
Operating Income Growth Recovery in ProgressRecovering
Percentile Rank74
3Y CAGR-13.0%
Year-over-Year Change
Year-over-year operating income growth rate
3Y CAGR
-13.0%/yr
vs +18.4%/yr prior
Acceleration
-31.5pp
Decelerating
Percentile
P74
Within normal range
vs 3Y Ago
0.7x
Contraction
Streak
1 qtr
Consecutive growthRecovering
| Period | Value |
|---|---|
| Q4 2025 | 23.01% |
| Q3 2025 | 19.19% |
| Q2 2025 | 22.70% |
| Q1 2025 | -8.98% |
| Q4 2024 | -3.32% |
| Q3 2024 | 1.11% |
| Q2 2024 | 79.65% |
| Q1 2024 | 53.31% |
| Q4 2023 | 63.88% |
| Q3 2023 | 1936.15% |
| Q2 2023 | 41.82% |
| Q1 2023 | 86.58% |
| Q4 2022 | 34.97% |
| Q3 2022 | -1.55% |
| Q2 2022 | 38.07% |
| Q1 2022 | -12.31% |
| Q4 2021 | 8.63% |
| Q3 2021 | 7.34% |
| Q2 2021 | -2.75% |
| Q1 2021 | 11.94% |
| Q4 2020 | -24.78% |
| Q3 2020 | 19.40% |
| Q2 2020 | -2.11% |
| Q1 2020 | -114.26% |
| Q4 2019 | 13.52% |
| Q3 2019 | 20.18% |
| Q2 2019 | 14.16% |
| Q1 2019 | 20.18% |
| Q4 2018 | -19.99% |
| Q3 2018 | -2.79% |
| Q2 2018 | 18.84% |
| Q1 2018 | -56.80% |
| Q4 2017 | 26.92% |
| Q3 2017 | -71.72% |
| Q2 2017 | -41.52% |
| Q1 2017 | -50.53% |
| Q4 2016 | -5.55% |
| Q3 2016 | 31.94% |
| Q2 2016 | -32.04% |
| Q1 2016 | -0.67% |